Arcturus Therapeutics (NASDAQ:ARCT) Releases Earnings Results, Beats Expectations By $0.06 EPS

Arcturus Therapeutics (NASDAQ:ARCT) announced its earnings results on Thursday. The biotechnology company reported ($0.95) EPS for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.06, FiscalAI reports. Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%. The firm had revenue of $2.06 million for the quarter, compared to analysts’ expectations of $6.30 million.

Here are the key takeaways from Arcturus Therapeutics’ conference call:

• Arcturus has begun enrollment in a 12-week open‑label Phase II of ARCT‑032 for Class 1 cystic fibrosis and reports patients have tolerated continuous inhaled dosing beyond one month, which the company attributes to its proprietary LUNAR delivery lipids and mRNA purification process.
• After a Type C meeting with the FDA, ARCT‑810 (OTC deficiency) received clear regulatory direction toward a pivotal pediatric development path; Arcturus is collecting additional exploratory data and plans an end‑of‑Phase II meeting in H2 2026.
• Financially, Arcturus reported $213.4 million in cash as of March 31, 2026 and says its cash runway extends beyond Q2 2028 following cost reductions and a strategic refocus on rare disease programs, despite a year‑over‑year revenue decline tied to reduced collaboration income.
• Partner Meiji is actively manufacturing Arcturus’ self‑amplifying mRNA COVID vaccine KOSTAIVE for Japan’s 2026/2027 season and will provide all commercial guidance, leaving Arcturus’ near‑term commercial exposure dependent on the partner.

Arcturus Therapeutics Trading Down 2.5%

NASDAQ:ARCT traded down $0.23 during mid-day trading on Thursday, reaching $8.90. The company’s stock had a trading volume of 488,566 shares, compared to its average volume of 333,320. Arcturus Therapeutics has a 12-month low of $5.85 and a 12-month high of $24.17. The firm’s fifty day moving average price is $7.89 and its two-hundred day moving average price is $7.83. The stock has a market cap of $252.94 million, a P/E ratio of -3.74 and a beta of 2.43.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Citigroup dropped their target price on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Piper Sandler dropped their target price on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Roth Mkm assumed coverage on Arcturus Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $20.00 price target for the company. B. Riley Financial assumed coverage on Arcturus Therapeutics in a research report on Wednesday, March 18th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Arcturus Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds have recently bought and sold shares of ARCT. Invesco Ltd. increased its position in shares of Arcturus Therapeutics by 59.9% during the 4th quarter. Invesco Ltd. now owns 103,116 shares of the biotechnology company’s stock valued at $632,000 after purchasing an additional 38,626 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at about $64,000. XTX Topco Ltd purchased a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at about $504,000. nVerses Capital LLC purchased a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at about $140,000. Finally, Susquehanna Portfolio Strategies LLC increased its position in shares of Arcturus Therapeutics by 7.5% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 103,077 shares of the biotechnology company’s stock valued at $632,000 after purchasing an additional 7,163 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.